Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nano-X Imaging Ltd.NNOX · Entity 7098 | Director | September 14, 2026 | September 15, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | January 01, 2018 | February 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nano-X Imaging Ltd.
Report date September 14, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 80,000 |
Reported balance
After 2026-09-14 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-09-14 · Purchase · Acquired 30,000 · Balance 80,000 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 110,000 |
Reported balance
After 2026-09-14 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-09-14 · Purchase · Acquired 30,000 · Balance 110,000 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 7,792 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,792 F1: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F2: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 17,544 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 17,544 F1: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F3: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $64.61 · Expires 2031-02-09 | Direct | 12,505 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 12,505 F1: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F4: The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.63 · Expires 2032-12-28 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 50,000 F1: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F5: The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and are fully vested and exercisable as of the date of this report. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $11.52 · Expires 2033-12-31 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 10,000 F1: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F6: The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027). |
Filing footnotes · ownership attribution and instrument terms
F1: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
F2: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.
F3: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.
F4: The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.
F5: The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and are fully vested and exercisable as of the date of this report.
F6: The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date January 01, 2018 · Filed February 12, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Put Option (Obligation to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.00 · Expires 2018-01-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-01-01 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance Not disclosed F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 15, 2026 12:00 UTC | Nano-X Imaging Ltd. NNOX · Entity 7098 | PurchaseOrdinary Shares | 30,000 | $0.75 | $22,500.00 |
DisclosureSEC source: 0001213900-26-099887 · ownership.xml · nonDerivative · entry 2 Suesskind Dan S · CIK 0001303873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 12:00 UTC | Nano-X Imaging Ltd. NNOX · Entity 7098 | PurchaseOrdinary Shares | 30,000 | $0.76 | $22,800.00 |
DisclosureSEC source: 0001213900-26-099887 · ownership.xml · nonDerivative · entry 1 Suesskind Dan S · CIK 0001303873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 07:40 UTC | Nano-X Imaging Ltd. NNOX · Entity 7098 | PurchaseOrdinary Shares | 25,000 | $0.92 | $23,000.00 |
DisclosureSEC source: 0001213900-26-082543 · ownership.xml · nonDerivative · entry 2 Suesskind Dan S · CIK 0001303873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 07:40 UTC | Nano-X Imaging Ltd. NNOX · Entity 7098 | PurchaseOrdinary Shares | 25,000 | $0.94 | $23,500.00 |
DisclosureSEC source: 0001213900-26-082543 · ownership.xml · nonDerivative · entry 1 Suesskind Dan S · CIK 0001303873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 20:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | OtherPut Option (Obligation to buy) · Derivative | 19,700 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004866 · doc4.xml · derivative · entry 2 Suesskind Dan S · CIK 0001303873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,700 shares Expires 2018-01-19 F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 20:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | OtherOrdinary Shares | 19,700 | $25.00 | $492,500.00 |
DisclosureSEC source: 0001209191-18-004866 · doc4.xml · nonDerivative · entry 1 Suesskind Dan S · CIK 0001303873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,836 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.